Biomolecular recognition via protein-protein interactions (PPI) is central to the signaling events in most physiological and pathological processes. Hence PPI are considered excellent targets for drug development. In recent years there is considerable interest in the design and development of peptide based drugs as antagonists or agonists of PPI. High potency, great selectivity and better safety profile are significant advantages of peptide therapeutics. The following is a brief review of the rationale and modifications in the design of peptide mimetics of PPI interface.
Hooft, R. W. W. (1998). Interface Peptide Mimetics-Rationale and Application as Therapeutic Agents. Medicinal Chemistry. OMICS International. https://doi.org/10.4172/2161-0444.1000344